About this trial
The Nordic Consortium for Acute Type A Aortic Dissection-2 (NORCAAD-2) is a multicenter research collaboration involving up to 19 units in the Nordic countries and one in The Netherlands. All patients referred for this condition is included, to outline detailed preoperative characteristics and risk factors as well as, for those operated, data on the operative procedure, the postoperative course including major and minor complications and, as the primary interest, mortality in short- and long-term perspective. The need for further procedures on the aorta will also be studied.
Acute type A Aortic Dissection (ATAAD) is a vascular emergency with very high case-fatality rate. The condition is realtively infrequent, and single units can rarely amass sufficient number of patients during a reasonable time to analyse also unusual variants in background, presentation, and management. Randomized controlled trials are unlikely, and large multicenter databases are the best source of knowledge for the foreseeable future. Other such databases exist, but NORCAAD-2 is more focused (only ATAAD) and more detailed than many counterparts, with the ability to extract unique information.
NORCAAD-2 is the extension and expansion of the original NORCAAD project. NORCAAD-2 includes more centers, more patients, more data and utilizes a novel on-line common database designed for the purpose.
The ultimate goal is to identify novel risk markers to help inform decisions on pre-emptive surgery (before ATAAD occurs); to outline superior perioperative techniques and strategies to optimize outcomes both short- and long-term; and to analyze variables related to major complications, in an effort to further reduce their incidence.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Acute (within 14 days of onset) type A aortic dissection or similar acute aortic syndrome
Disqualifiers
Age <18 years at onset
Trial population
All patients with acute type A aortic dissection referred to any of the participating centers
Trial design
Case-only
Prospective
Treatments tested in this trial
surgery
Procedure/SurgeryOpen heart surgery
endovascular intervention
Procedure/SurgeryAortic endovascular intervention
Treatment groups
Trial outcomes
Primary outcomes
Early mortality
Mortality within 30 days of referral or operation
Secondary outcomes
Late mortality
Mortality late after referral or operation
Reintervention
Any reintervention (endovascular, open surgical) on the aorta
Other outcomes
Permanent neurological damage
Stroke or spinal cord infarction with permament neurological symptoms
Temporary neurological damage
Transitory ischemic attack, minor stroke, coma or unconsciousness, confusion or other new neurological symptoms resolving before discharge
Renal insufficiency
Renal insufficiency (as graded and described by various classification systems)
Re-exploration
Re-exploration for control of bleeding or tamponade
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Karolinska Institutet
Lead sponsor
Aarhus University Hospital Skejby
Collaborator
Haukeland University Hospital
Collaborator
Rigshospitalet, Denmark
Collaborator
Helsinki University Central Hospital
Collaborator
Kuopio University Hospital
Collaborator
Leiden University Medical Center
Collaborator
Skane University Hospital
Collaborator
Odense University Hospital
Collaborator
Oslo University Hospital
Collaborator
Landspitali University Hospital
Collaborator
Norrlands University Hospital
Collaborator
Tampere University Hospital
Collaborator
Turku University Hospital
Collaborator
Trondheim University Hospital
Collaborator
University Hospital, Linkoeping
Collaborator
Vastra Gotaland Region
Collaborator
Uppsala University Hospital
Collaborator
Blekinge County Council Hospital
Collaborator
Örebro University, Sweden
Collaborator
Riga Stradins University
Collaborator